Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IQIYI Inc - ADR (IQ) vs Philip Morris International Inc. (PM) Price & Performance

IQIYI Inc - ADRTrade
Philip Morris International Inc.Trade

Price performance (Past 24H)

Key statistics

IQIYI Inc - ADR vs Philip Morris International Inc. — how do they compare? IQIYI Inc - ADR trades at $1.02 (market cap $979.50M), while Philip Morris International Inc. trades at $199.75 (market cap $300.33B). The key difference: Philip Morris International Inc. is far larger — about 306.6× IQIYI Inc - ADR's market cap, and Philip Morris International Inc. pays a 3.32% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Philip Morris International Inc. for 85 Days on average.

IQPM
Market Cap
$979.50M$300.33B
Volume
1,962,9503,935,700
Sector
MediaConsumer Staples
52-Week High
$2.35$200.50
52-Week Low
$0.86$144.33
Typical Hold Time
55 Days85 Days
Enterprise Value
$2.47B$343.44B
Dividend Yield
—3.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IQIYI Inc - ADR

iQIYI (IQ) trades at $1.01, showing no change in the latest session. The stock presents a mixed picture with strong analyst support (50% buy ratings) but concerning fundamentals including negative net income margins and declining revenue. Recent earnings have consistently beaten expectations despite losses, while the company is aggressively pursuing AI-driven content production to reset its cost structure amid streaming business contraction.

The outlook remains challenging with revenue declining to $27.3 billion in 2025 and projected to fall further to $26.0 billion in 2026. While valuation metrics appear attractive with P/S of 0.25 and P/B of 0.52, persistent losses and competitive pressures in Chinese streaming markets create significant headwinds. The AI content pivot offers potential but requires successful execution to justify current analyst optimism.

Philip Morris International Inc.

Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.

Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IQ

No sentiment data available yet.

PM
10% Buy90% Sell
Avg holding period · 85 Days

Top news

Latest headlines on both assets

About IQIYI Inc - ADR

iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.

Read more on IQ →

About Philip Morris International Inc.

Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.

Read more on PM →